We are live on ! Find out more
KNTE

Kinnate Biopharma Inc. Common Stock
KNTE

Delisted

KNTE was delisted on the 2nd of April, 2024.

Back to rankings

73 hedge funds and large institutions have $905M invested in Kinnate Biopharma Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 32 increasing their positions, 9 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

256% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 9

183% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 6

18% more funds holding

Funds holding: 62 → 73 (+11)

2% more capital invested

Capital invested by funds: $891M → $905M (+$14.4M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
73
Holders Change
+11
Holders Change %
+17.74%
% of All Funds
1.28%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
17
Increased
32
Reduced
9
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
+$17M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$14.6M
3
BlackRock
BlackRock
New York
+$13.1M
4
Morgan Stanley
Morgan Stanley
New York
+$6.88M
5
NHAS
Novo Holdings A/S
Denmark
+$4.32M

Top Sellers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
-$26.9M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$10.4M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$10.4M
4
Franklin Resources
Franklin Resources
California
-$4.47M
5
Citadel Advisors
Citadel Advisors
Florida
-$3.19M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$3.07M +$942K +43,288 +48%
Deutsche Bank
27
Deutsche Bank
Germany
$3.06M +$143K +6,555 +5%
Janus Henderson Group
28
Janus Henderson Group
United Kingdom
$2.92M -$10.4M -475,709 -79%
AG
29
Artal Group
Luxembourg
$2.88M – – –
Millennium Management
30
Millennium Management
New York
$2.73M +$2.58M +118,734 New
DCM
31
DAFNA Capital Management
California
$2.45M +$1.13M +52,038 +96%
N
32
Nuveen
North Carolina
$2.2M +$825K +37,893 +66%
Victory Capital Management
33
Victory Capital Management
Texas
$2.19M -$16.8K -770 -0.8%
Goldman Sachs
34
Goldman Sachs
New York
$2.18M +$1.73M +79,349 +522%
LGM
35
Logos Global Management
California
$2.17M -$26.9M -1,235,257 -93%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$1.54M +$572K +26,267 +65%
HS
37
HighVista Strategies
Massachusetts
$1.4M +$599K +27,514 +82%
RhumbLine Advisers
38
RhumbLine Advisers
Massachusetts
$690K +$316K +14,517 +94%
D.E. Shaw & Co
39
D.E. Shaw & Co
New York
$655K +$168K +7,711 +37%
PPA
40
Parametric Portfolio Associates
Washington
$620K +$586K +26,923 New
Swiss National Bank
41
Swiss National Bank
Switzerland
$552K – – –
Renaissance Technologies
42
Renaissance Technologies
New York
$538K -$273K -12,542 -35%
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$526K +$89.9K +4,130 +22%
Russell Investments Group
44
Russell Investments Group
United Kingdom
$516K +$489K +22,455 New
Bank of America
45
Bank of America
North Carolina
$446K +$307K +14,109 +268%
State of Wisconsin Investment Board
46
State of Wisconsin Investment Board
Wisconsin
$403K +$381K +17,500 New
SG Americas Securities
47
SG Americas Securities
New York
$354K +$335K +15,385 New
Ensign Peak Advisors
48
Ensign Peak Advisors
Utah
$345K – – –
AIG
49
American International Group
New York
$324K +$141K +6,489 +85%
Manulife (Manufacturers Life Insurance)
50
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$318K +$301K +13,805 New
1
2
3 4

KNTE Hedge Fund Activity: Q3 2021 in Review

73 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q3 2021, worth a combined $905M — up 1.6% from $891M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new KNTE positions and 6 closed out — a net gain of 11 holders — while 32 added to existing stakes and 9 trimmed.

The largest buyer was Boxer Capital, adding an estimated $17M. The largest seller was Logos Global Management, cutting an estimated $26.9M.

  • 73 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q3 2021, up from 62 in Q2 2021.
  • Funds reported $905M of Kinnate Biopharma Inc. Common Stock stock for Q3 2021, up 1.6% quarter-over-quarter.
  • 17 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q3 2021 and 6 closed out, a net change of +11 holders.
  • The largest Kinnate Biopharma Inc. Common Stock buyer in Q3 2021 was Boxer Capital, an estimated $17M added.
  • The largest Kinnate Biopharma Inc. Common Stock seller in Q3 2021 was Logos Global Management, an estimated $26.9M sold.

Based on aggregated 13F filings for Q3 2021.